Update, November 4, 2026: A unanimous jury returned a verdict for Mead Johnson on August 31. Reuters reported that the jury found Enfamil did not cause the infant’s NEC. It was the first federal jury to hear the plaintiffs’ causation experts. Four federal bellwethers have now ended for the defense, three at summary judgment and one at trial. Mead Johnson says no NEC jury verdict against it remains outstanding, counting two state trial wins and the Watson reversal.
Abbott settled before the verdict came in. On August 20 it agreed to pay about $670 million to resolve the Gill case and the NEC claims of roughly 2,000 more infants. Gill is the Missouri case behind the $495 million verdict discussed below, and Abbott’s filing puts that judgment near $600 million with interest. Abbott called the agreements a compromise of disputed claims and not an admission of liability. Its filing says about 1,700 NEC lawsuits remain pending in federal and state courts, covering about 12,700 infants.
The federal docket has not shrunk. The Panel’s November 2 report counts 847 actions pending in MDL 3026, up from about 825 when the trial opened. Abbott’s filing does not say how many of the settled claims sit in the MDL. Mead Johnson has said it will keep defending the cases. For the Similac cases Abbott has not settled, the Seventh Circuit’s warning-causation holding in Mar, discussed below, still sets the terms.
The next contest is over where the remaining cases are heard. Abbott has asked the court to enter a case management order it proposed. On October 23 a large group of plaintiffs, Alexis Inman among them, opposed that order in the same filing as a motion to remand. Judge Pallmeyer extended Abbott’s deadline to reply to November 6. Her ruling on the motion is the next entry to watch on this docket.
The NEC infant formula litigation has been running for four years without a federal jury ever hearing it. That changed this week in Chicago, where Inman v. Mead Johnson is being tried before Judge Rebecca Pallmeyer. She has presided over MDL 3026 since the Panel centralized the preterm infant nutrition cases in the Northern District of Illinois. Roughly 825 cases are pending on the federal docket, with hundreds more in state court.
The plaintiff, Alexis Inman, alleges that her son Daniel was born at 29 weeks. In the NICU he moved from fortified breast milk to exclusive feeding with Mead Johnson's Enfamil Premature product. He developed necrotizing enterocolitis, underwent surgery on June 22, 2020, and died the next day. The claims are failure to warn and design defect, the latter resting on the argument that a different carbohydrate formulation was available and safer.
Plaintiff-side announcements are calling this the first bellwether trial. It is more precisely the first bellwether to reach a jury. Three earlier bellwethers were tried only in the sense that they were worked up, scheduled, and then lost before openings. Losing before openings is a different fact pattern, and a more instructive one.
Three cases that died at the gate
The first wave of MDL bellwethers all involved Abbott's Similac. In each, Pallmeyer excluded the plaintiffs' causation experts and granted summary judgment, so no jury heard the evidence. Read against a state-court record that includes a half-billion-dollar verdict, that divergence looks strange until you separate the two questions being asked. State juries were asked whether cow's-milk-based preterm formula causes NEC and whether the manufacturers said enough about it. The federal court was asked, first, whether the expert methodology clears Rule 702, and the answer three times was no.
Inman is different for a narrow procedural reason. The court denied Mead Johnson's summary judgment motion in May and preserved the plaintiff's epidemiology testimony. The jury will hear plaintiff experts on causation for the first time in the federal docket. That is the entire significance of the trial date. Everything else being said about it this week is atmosphere.
Worth noting for anyone who plans around trial calendars: this case was set for February, then July 6, then mid-August. Three announced dates for one trial is normal in a large MDL and abnormal in the press releases written about them.
The state record is not the tailwind it looks like
The plaintiff-side numbers are real. A Missouri jury returned $495 million against Abbott in 2024, and that verdict survived appeal. A Cook County jury awarded $70 million to four families in April, roughly $53 million compensatory and $17 million punitive, after a short deliberation. The aggregate across state verdicts is north of $625 million.
The erosion is also real, and it is more recent. On June 16 an Illinois appellate court reversed the $60 million Watson verdict against Mead Johnson, the first NEC verdict in the country. The court cited jury instruction error and ordered a new trial. Two weeks later a St. Louis jury returned a defense verdict for Mead Johnson in the Collins case.
The only defense verdict that had been vacated for trial misconduct is itself on appeal. A verdict is not money until it survives review, and this docket has now demonstrated that at both ends.
Warning causation is the variable that prices the inventory
The most consequential ruling of the summer was not in Chicago. On July 24 the Seventh Circuit affirmed dismissal in Mar v. Abbott, one of the original bellwethers. It held that the plaintiff could not show a stronger NEC warning would have changed anything. In the court's account, the treating physicians already understood the risk and had no viable alternative to fortified formula for that infant at that time.
That is a learned-intermediary holding with a feeding-practice overlay, and it does not depend on the science being weak. It means the questions that decide a case are hospital-specific and date-specific. Did that NICU have a donor milk program in place. Was maternal milk available in sufficient volume. What did the treating neonatologist know about NEC risk, and what will that neonatologist say in deposition about whether a different label would have altered the feeding order.
Firms evaluating NEC inventory on gestational age and diagnosis alone are underwriting a different tort than the one the Seventh Circuit just described.
Durnell shows up in formula
On August 5 the court denied Mead Johnson's motion arguing that the Supreme Court's Roundup preemption decision in Monsanto v. Durnell controls here. In Mead Johnson's version, the Infant Formula Act stands in for the federal labeling scheme at issue there. The denial was without prejudice, which means the argument returns after trial and in every case behind this one.
The cross-tort point is the one to keep. Durnell was decided in a herbicide case and is now being run in a food and drug regulatory context within months. Any tort where a federal statute touches the label should expect the same motion. The useful question is how much calendar the motion consumes when it is filed in a thousand cases at once, whether or not it wins.
What a verdict does
A plaintiff verdict gives the federal docket its first data point and changes the posture of roughly 825 cases plus the state inventory. It would also cut against the read that has developed since the first-wave dismissals, which is that the federal forum is structurally hostile to these claims. A defense verdict makes it four federal failures out of four and leaves plaintiffs with a state-court record that appellate courts have started trimming.
The exposure estimates in circulation should be read as ranges rather than figures. Bloomberg Intelligence has put total liability in the low billions; plaintiff-side materials this week cite analyst estimates running from the hundreds of millions to several billion pounds. The gap between those numbers is the same gap the jury is about to address, and neither end of it is a settlement value.
What moves that number is whether the second bellwether wave produces a pattern. It also turns on whether the warning-causation record holds up when the next case has a NICU with a donor milk program in it.
For where this sits alongside the other dockets moving this year, see the 2026 mass tort map.